ESPR · Esperion Therapeutics, Inc.

Current Thesis

Esperion Therapeutics’ cash-merger thesis was settled by ARCHIMED’s acquisition on 2026-07-13; the remaining commercial milestones concern an unlisted contingent right, not an ongoing ESPR equity price. ARCHIMED’s completion announcement specifies $3.16 per share in cash and contingent payments of up to $100 million in aggregate, and confirms that the common stock ceased trading. ARCHIMED, 2026-07-13

The interpretation remains that the narrative is dead — the 2026-07-13 completion ended the listed merger-convergence story through completion. As checked on 2026-09-13, Esperion’s newsroom still leads with its 2026-05-26 scientific presentation announcement; that page supplies no subsequent operating update that changes the completed-transaction frame. This is a bounded observation about the company’s newsroom, not proof that private milestone progress has stopped. Esperion newsroom

Bullish and bearish views on Esperion Therapeutics, Inc.

The model's bull view on Esperion Therapeutics, Inc. (ESPR), in brief: The acquisition actually completed. Esperion’s 2026-07-13 Form 8-K records consummation of the merger and the company becoming a wholly owned subsidiary. Completion is an observed outcome, rather than an outstanding approval or financing catalyst. Closing Form 8-K The commercial… The bear view: Listed participation has ended. ARCHIMED’s 2026-07-13 announcement confirms that Esperion common stock is no longer listed on Nasdaq. The completed acquisition therefore supplies no continuing public equity instrument through which the commercial milestones can be priced.… Both cases follow in full.

Bull Case

• The acquisition actually completed. Esperion’s 2026-07-13 Form 8-K records consummation of the merger and the company becoming a wholly owned subsidiary. Completion is an observed outcome, rather than an outstanding approval or financing catalyst. Closing Form 8-K

• The commercial right includes partial payment. The 2026-05-01 transaction announcement provides an interpolated bempedoic-acid payment when calendar-2027 annual U.S. net sales exceed $300 million but remain below $350 million. Describing the entire right as dependent on exceeding $350 million omits this contractual feature. Esperion transaction announcement

Bear Case

• Listed participation has ended. ARCHIMED’s 2026-07-13 announcement confirms that Esperion common stock is no longer listed on Nasdaq. The completed acquisition therefore supplies no continuing public equity instrument through which the commercial milestones can be priced. ARCHIMED completion announcement

• Contractual payments remain conditional. The 2026-05-01 terms describe the contingent value right (CVR) as non-tradeable. They require product-specific U.S. sales milestones; the existence of the contract supplies no evidence that those milestones have been achieved. Esperion transaction announcement

Setup & Price Structure

The supplied adjusted daily-bar series records a final reference close of $3.18 on 2026-07-10 and a three-month price increase of 46.5%. Those observations describe the pre-completion market. The 2026-07-13 cessation of trading prevents interpreting that historical increase as continuing momentum. ARCHIMED completion announcement

Current crowding cannot be established from the supplied evidence. No dated retail-participation, short-interest or moving-average series accompanies the 2026-07-10 reference close. The supplied scientific headlines dated 2026-05-13 and 2026-05-26 are too small a sample to support a claim about sentiment clustering.

Catalyst Calendar (next 30 days)

As of 2026-09-13, no company-confirmed event in the next 30 days was identified in the reviewed announcements. Esperion’s newsroom still displays 2026-05-26 as its latest announcement; a customary earnings slot is not a confirmed catalyst. Esperion newsroom

• 2027-12-31 — Bempedoic-acid measurement window ends. The 2026-05-01 terms specify calendar-2027 U.S. net sales and an aggregate $40 million payment above $350 million. This is a contractual measurement deadline, not an announced disclosure or payment date. Transaction terms

• 2030-12-31 — Bumetanide milestone window ends. The same terms specify an aggregate $60 million payment if annual U.S. net sales reach at least $160 million in any single calendar year through that date. No probability of achievement is established by those terms. Transaction terms

What Would Change Our Mind

An exchange-confirmed listing of Esperion equity would overturn the present conclusion that no listed setup exists. The historical price condition, a daily close below $3.16, refers to the cash consideration documented on 2026-07-13; it cannot operate as a live invalidation after cancellation of the common stock. A future listing would require its own security identification and price structure. Closing Form 8-K

The cash-merger case has already played out. The 2026-07-13 completion does not establish whether the separate commercial milestones will pay. ARCHIMED completion announcement

Correlation Notes

This remains a single-company transaction analysis: the decisive observed event is the 2026-07-13 merger completion. No paired return series is supplied to establish a relationship with biotechnology shares, interest rates or another market factor. The final 2026-07-10 reference close cannot establish a post-completion correlation.